SCHEMBL7513626

SCHEMBL7513626

CN1CCN(Cc2ccc(-c3cnc4[nH]cc(I)c4c3)cc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNIK Q9UKE5 11/20 0.75
MAP3K11 Q16584 10/20 0.71
IKBKB O14920 2/20 0.70
CHUK O15111 2/20 0.70
ABL1 P00519 2/20 0.70
INSR P06213 2/20 0.70
CDK2 P24941 2/20 0.70
FLT3 P36888 2/20 0.70
MAP4K1 Q92918 1/20 0.68
SGK1 O00141 1/20 0.67
AURKA O14965 1/20 0.67
PRKAB2 O43741 1/20 0.67
ROCK2 O75116 1/20 0.67
NTRK1 P04629 1/20 0.67
LCK P06239 1/20 0.67
CDK1 P06493 1/20 0.67
IGF1R P08069 1/20 0.67
MET P08581 1/20 0.67
CYP3A4 P08684 1/20 0.67
SRC P12931 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15154822 0.92 MAP3K11 (0.84) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL22971590 0.86 TNIK (1.00) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL12067551 0.85 TNIK (0.83) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL22971593 0.85 TNIK (0.79) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL12065847 0.85 TNIK (0.83) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL12066034 0.85 TNIK (1.00) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL22971634 0.85 TNIK (0.83) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL12065823 0.85 TNIK (0.79) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL12065828 0.85 TNIK (0.79) TNIKMAP3K11IKBKBCHUKABL1
SCHEMBL22971652 0.84 TNIK (0.78) TNIKMAP3K11IKBKBCHUKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382291-A1 SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS UNIV COLUMBIA (US) 2025-12-18 US disclosed
US-12227500-B2 Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2025-02-18 US disclosed
US-20210040091-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS UNITED STATES GOVERNMENT 2021-02-11 US disclosed
US-20210040091-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS UNITED STATES GOVERNMENT 2021-02-11 US disclosed
CN-112243439-A Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2021-01-19 CN disclosed
EP-2925319-B1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIV ROCHESTER (US) 2019-01-09 EP disclosed
CN-103153994-B Bicyclic heteroaryl kinase inhibitor and using method UNIVERSITY OF ROCHESTER (US) 2016-02-10 CN disclosed
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-10-22 US disclosed
EP-2925319-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES University Of Rochester (US) 2015-10-07 EP disclosed
CN-104884059-A Mixed lineage kinase inhibitors for hiv/aids therapies UNIV ROCHESTER 2015-09-02 CN disclosed
US-8846909-B2 Bicyclic heteroaryl kinase inhibitors and methods of use UNIVERSITY OF ROCHESTER (US) 2014-09-30 US disclosed
WO-2014085795-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES UNIVERSITY OF ROCHESTER (US) 2014-06-05 WO disclosed
US-20130203755-A1 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2013-08-08 US disclosed
CN-103153994-A Bicyclic heteroaryl kinase inhibitors and methods of use UNIV ROCHESTER 2013-06-12 CN disclosed
EP-2576549-A2 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE University of Rochester (US) 2013-04-10 EP disclosed
WO-2011149950-A2 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE UNIVERSITY OF ROCHESTER (US) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210040091-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS HSPA5, ATP2A1, DNAJC10 TNIK 2690/4885MAP3K11 3182/4885IKBKB 1558/4885
US-12227500-B2 Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress HSPA5, ATP2A1, DNAJC10 TNIK 2737/4885MAP3K11 2583/4885IKBKB 1016/4885
US-20150297587-A1 MIXED LINEAGE KINASE INHIBITORS FOR HIV/AIDS THERAPIES MLKL, MARCKS, MAP3K4 TNIK 81/4885MAP3K11 25/4885IKBKB 285/4885
US-20250382291-A1 SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS HSPA5, ATP2A1, DNAJC10 TNIK 2737/4885MAP3K11 2583/4885IKBKB 1016/4885
US-20130203755-A1 BICYCLIC HETEROARYL KINASE INHIBITORS AND METHODS OF USE MAP2K2, MAP2K7, CHKB TNIK 314/4885MAP3K11 45/4885IKBKB 487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.